NMRA Stock Analysis: Buy, Sell, or Hold?
NMRA - Neumora Therapeutics, Inc. Common Stock
$1.84
-0.13 (-6.60%)
▼
5d:
+0.55%
30d:
-8.0%
90d:
-42.5%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Accumulation
NMRA is down 23.6% this week, but smart money is accumulating calls. Top strike: $2.5 2026-07-17 with 8,274 OI. Call ratio: 72% View Scanner →
Strength: 10.0/10
Get Alerted When NMRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NMRA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NMRA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NMRA is currently trading at $1.84, which is considered slightly low relative to its 30-day fair value range of $1.96 to $2.31.
Technical Outlook: Technically, NMRA is showing sideways momentum. Immediate support is located at $1.74, while resistance sits at $2.48. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: NMRA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.91 (+384.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NMRA is showing sideways momentum. Immediate support is located at $1.74, while resistance sits at $2.48. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: NMRA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.91 (+384.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.96 -
$2.31
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.6%)
- BULLISH: Trading 384.1% below Wall St target ($8.91)
Trading Range Analysis
30-Day Trading Range
$1.96 -
$2.31
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.74
Resistance Level
$2.48
Current Trend
Sideways
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.09
Wall Street Target
$8.91
(+384.1%)
Share & Embed Analysis
Last updated: May 16, 2026 8:24 AM ET
Data refreshes hourly during market hours. Next update: 9:24 AM
Data refreshes hourly during market hours. Next update: 9:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NMRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Daljit Singh Aurora
SELL
6165 shares
2026-02-17
Joshua Pinto
SELL
5967 shares
2026-02-17
Michael Lee Milligan
SELL
1436 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 60 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$104 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |